Receptor Life Sciences

Inhaled Dry Powder CBD For Epileptic Seizures: Receptor Life Sciences' FDA Drug Application

Receptor Life Sciences (RLS), a pharmaceutical company developing innovative therapies to address central nervous system disorders, recently announced it’s expanding the potential clinical utility of RLS103, a dry powder inhaled cannabidiol (CBD) into epilepsy treatment.

FDA Says Yes To Testing Receptor Life's Dry Power Inhaled CBD To Treat Social Anxiety Disorder

The FDA accepted Receptor Life Sciences’ investigational new drug application for RLS103. RLS103, a dry powder inhaled CBD, which is a first-in-class drug/device combination product for the acute treatment of social anxiety disorder.